Creative Medical Technology shares shareholder letter on clinical progress

Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) released a shareholder letter from Chief Executive Officer Timothy Warbington detailing the company's clinical trial progress and business developments.

The biotechnology company is conducting two FDA-cleared clinical trials using its AlloStem platform. The CELZ-201-DDT trial targets chronic lower back pain from degenerative disc disease and has received FDA Fast Track Designation, with topline results expected in the first half of 2026. The CREATE-1 trial focuses on new-onset Type 1 diabetes, with early data anticipated in 2026.

Creative Medical reported manufacturing over 6 billion clinical-grade cells under current Good Manufacturing Practice standards for its AlloStem technology. The company operates three cellular platforms: AlloStem for off-the-shelf donor-derived treatments, ImmCelz for personalized immunotherapy, and iPScelz for induced pluripotent stem cells.

The company's intellectual property portfolio includes over 60 patents and pending applications. During the third quarter of 2025, Creative Medical secured two U.S. patents expanding ImmCelz coverage to Type 1 diabetes treatment, expiring in 2043, and heart failure treatment, expiring in 2042.

Creative Medical has integrated artificial intelligence into its iPScelz platform for target discovery, donor cell selection optimization, and simulation of cellular behavior before clinical testing. The company describes this approach as advancing personalized regenerative medicine.

The letter emphasized the company's focus on capital efficiency and operational discipline while advancing multiple clinical programs. Creative Medical positions itself as developing treatments across multiple therapeutic areas rather than focusing on a single product approach.

You May Also Be Interested In

• Modular Medical begins U.S. sales of Pivot insulin patch pump
• OFA Group launches QikBIM AI platform for commercial use
• Enlivex RAIN token listed on Gate cryptocurrency exchange